blood poisoning Sepsis
Conditions
Interventions
None listed
Sponsors
Wageningen Universiteit
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Septic ICU patients: - 18+ years of age - Diagnosed with sepsis, not origniated from the urinary system Control patients: - Short-stay hospitalised patients (e.g. admission for one day), or patients admitted to the outpatient clinic of Gelderse Vallei Hospital - Free of sepsis - Metabolically healthy - Age (+/- 2 years) and gender-matched
Exclusion criteria
Exclusion criteria: *Only applicable for septic ICU patients **Comprehensively described in appendix of the protocol (All pre-ICU admission notes are not applicable to control patients), • Patients referred from another ICU • Patients with a haemoglobin level lower than 5,5 mmol/lL* • Patients with a history of solid organ or bone marrow transplant • Patients with active autoimmune disease involving the lung, heart, liver, small or large intestine, or neuromuscular system (e.g., myasthenia gravis, multiple sclerosis) AND currently requiring systemic immunosuppressive therapy • Patients whom experienced a significant medical or surgical event leading to hospitalization within the previous 6 months • Patients with a disease process (e.g., end-stage cancer) with a projected survival of less than 6 months (pre-ICU admission) • Patients whom received treatment with chemotherapy, immunotherapy or radiotherapy within the past 12 months • Patients with a family history of mitochondrial disease(s) ** • Patients with COPD Gold-Stadium III or IV or other severe respiratory disorders (FEV1 2.5 alcoholic beverages/day) • Patients with a history of drug abuse • Patients whom received treatment with corticosteroids or other immunosuppressive medications for active autoimmune disease involving the lung, heart, liver, small or large intestine, or neuromuscular system within 3 months prior to ICU-stay NOTE: Topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption) are permitted
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study parameter is mitochondrial function in PBMCs. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary study parameters are (a) parameters of hypermetabolic inflammatory status (concentrations of catabolic hormones, nutrients in serum/plasma, catabolic/pro-inflammatory cytokines and anabolic hormones), (b) mitochondrial dynamics and autophagy and (c) data from medical records. | — |
Countries
Netherlands
Outcome results
None listed